269 related articles for article (PubMed ID: 26940805)
1. A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.
Haig GM; Bain EE; Robieson WZ; Baker JD; Othman AA
Am J Psychiatry; 2016 Aug; 173(8):827-35. PubMed ID: 26940805
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers.
Haig GM; Wang D; Zhao J; Othman AA; Bain EE
J Clin Psychiatry; 2018; 79(3):. PubMed ID: 28922590
[TBL] [Abstract][Full Text] [Related]
3. The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.
Haig G; Wang D; Othman AA; Zhao J
Neuropsychopharmacology; 2016 Nov; 41(12):2893-2902. PubMed ID: 27319970
[TBL] [Abstract][Full Text] [Related]
4. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
Keefe RS; Meltzer HA; Dgetluck N; Gawryl M; Koenig G; Moebius HJ; Lombardo I; Hilt DC
Neuropsychopharmacology; 2015 Dec; 40(13):3053-60. PubMed ID: 26089183
[TBL] [Abstract][Full Text] [Related]
5. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
[TBL] [Abstract][Full Text] [Related]
7. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.
Umbricht D; Keefe RS; Murray S; Lowe DA; Porter R; Garibaldi G; Santarelli L
Neuropsychopharmacology; 2014 Jun; 39(7):1568-77. PubMed ID: 24549101
[TBL] [Abstract][Full Text] [Related]
8. A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.
Lieberman JA; Dunbar G; Segreti AC; Girgis RR; Seoane F; Beaver JS; Duan N; Hosford DA
Neuropsychopharmacology; 2013 May; 38(6):968-75. PubMed ID: 23303043
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia.
Haig GM; Bain E; Robieson W; Othman AA; Baker J; Lenz RA
Schizophr Bull; 2014 Nov; 40(6):1433-42. PubMed ID: 24516190
[TBL] [Abstract][Full Text] [Related]
10. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study.
Fleischhacker WW; Podhorna J; Gröschl M; Hake S; Zhao Y; Huang S; Keefe RSE; Desch M; Brenner R; Walling DP; Mantero-Atienza E; Nakagome K; Pollentier S
Lancet Psychiatry; 2021 Mar; 8(3):191-201. PubMed ID: 33610228
[TBL] [Abstract][Full Text] [Related]
12. Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia.
Preskorn SH; Gawryl M; Dgetluck N; Palfreyman M; Bauer LO; Hilt DC
J Psychiatr Pract; 2014 Jan; 20(1):12-24. PubMed ID: 24419307
[TBL] [Abstract][Full Text] [Related]
13. Galantamine for the treatment of cognitive impairments in people with schizophrenia.
Buchanan RW; Conley RR; Dickinson D; Ball MP; Feldman S; Gold JM; McMahon RP
Am J Psychiatry; 2008 Jan; 165(1):82-9. PubMed ID: 17986678
[TBL] [Abstract][Full Text] [Related]
14. Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis.
Kishi T; Ikuta T; Oya K; Matsunaga S; Matsuda Y; Iwata N
Int J Neuropsychopharmacol; 2018 Aug; 21(8):748-757. PubMed ID: 29762677
[TBL] [Abstract][Full Text] [Related]
15. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
Javitt DC; Buchanan RW; Keefe RS; Kern R; McMahon RP; Green MF; Lieberman J; Goff DC; Csernansky JG; McEvoy JP; Jarskog F; Seidman LJ; Gold JM; Kimhy D; Nolan KS; Barch DS; Ball MP; Robinson J; Marder SR
Schizophr Res; 2012 Apr; 136(1-3):25-31. PubMed ID: 22169248
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
Brown D; Nakagome K; Cordes J; Brenner R; Gründer G; Keefe RSE; Riesenberg R; Walling DP; Daniels K; Wang L; McGinniss J; Sand M
Schizophr Bull; 2019 Mar; 45(2):350-359. PubMed ID: 29718385
[TBL] [Abstract][Full Text] [Related]
17. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia.
Zhang XY; Liu L; Liu S; Hong X; Chen DC; Xiu MH; Yang FD; Zhang Z; Zhang X; Kosten TA; Kosten TR
Am J Psychiatry; 2012 Sep; 169(9):974-81. PubMed ID: 22952075
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.
Walling D; Marder SR; Kane J; Fleischhacker WW; Keefe RS; Hosford DA; Dvergsten C; Segreti AC; Beaver JS; Toler SM; Jett JE; Dunbar GC
Schizophr Bull; 2016 Mar; 42(2):335-43. PubMed ID: 26071208
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
Keefe RS; Fox KH; Harvey PD; Cucchiaro J; Siu C; Loebel A
Schizophr Res; 2011 Feb; 125(2-3):161-8. PubMed ID: 21075600
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended-Release Formulation.
Kem WR; Olincy A; Johnson L; Harris J; Wagner BD; Buchanan RW; Christians U; Freedman R
Neuropsychopharmacology; 2018 Feb; 43(3):583-589. PubMed ID: 28825423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
